Replies to post #308514 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Regarding the rindo P3 study:

The study was terminated at the second preplanned interim analysis after 212 deaths had occurred in the MRD study population, with the hazard ratio for rindopepimut versus control, equal to 0.99 (95% CI: 0.74–1.31) demonstrating that rindopepimut was unlikely to be better than control. A similar lack of benefit was discovered in the intention-to-treat population. Surprisingly, there was suggestion toward improved survival of patients treated with rindopepimut in the exploratory analysis of patients with significant residual disease, although this effect was less pronounced when tumor burden was defined by each investigator rather than central review. The study confirmed findings of earlier phase clinical trials showing that, rindopepimut induces a moderate to rapid EGFRvIII-specific antibody response in the majority of patients, which suggests that failure to generate an immune response was not a primary reason for the lack of improved survival. Patients with rapid development of a humoral response trended toward better outcomes, although this data did not reach statistical significance. Interestingly, the loss of EGFRvIII expression was described in ~57–59% of GBM tumors post-treatment and regardless of whether rindopepimut or control treatment was administered, which is consistent with another recent study (2,7). These new data suggest that EGFRvIII loss is not due to immunization with rindopepimut, but rather, is inherent to the natural evolution intrinsic to GBM progression. Coincident with this finding is the loss of patient GBM EGFRvIII expression was independent of EGFRvIII antibody titers.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166880/

It didn't work.